Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)

HARROW, INC.

2025-Q3 EPS reported -$0.32 vs consensus $0.27 ▼ miss (-219.1%)

Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M
VEVYE revenue $22.6M (+22% QoQ); national DED market share 10.5% (up 2.7pp); coverage agreements with largest PBM effective Jan 2026
IHEEZO revenue $21.9M (+70% YoY); on track to exceed $50M annual revenue by year-end 2025
Agreed to acquire Melt Pharmaceuticals (MELT-300) for non-opioid sedation; refinancing cut interest ~$3M/yr, added $50M liquidity

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.